GRC-201
Treatment-Resistant Focal Onset Seizures
Phase 1/2Active
Key Facts
Indication
Treatment-Resistant Focal Onset Seizures
Phase
Phase 1/2
Status
Active
Company
About Grace Therapeutics
Grace Therapeutics is dedicated to transforming the treatment landscape for patients with severe neurological conditions through innovative science. The company's core strategy involves targeting validated pathways with novel mechanisms of action to improve efficacy and safety profiles. With a lead asset in mid-stage clinical trials and a strong leadership team with deep industry experience, Grace is positioned to generate critical proof-of-concept data. The company's public listing provides a foundation for funding its development programs and pursuing strategic growth.
View full company profile